Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl

Kumaravel Somasundaram, Hongbing Zhang, Yi-Xin Zeng, Yariv Houvras, Yi Peng, Hongxiang Zhang, Gen Sheng Wu, Jonathan D. Licht, Barbara L. Weber and Wafik S. El-Deiry ()
Additional contact information
Kumaravel Somasundaram: Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, University of Pennsylvania School of Medicine
Hongbing Zhang: University of Pennsylvania School of Medicine
Yi-Xin Zeng: Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, University of Pennsylvania School of Medicine
Yariv Houvras: The Mount Sinai School of Medicine
Yi Peng: University of Pennsylvania School of Medicine
Hongxiang Zhang: University of Pennsylvania School of Medicine
Gen Sheng Wu: Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, University of Pennsylvania School of Medicine
Jonathan D. Licht: The Mount Sinai School of Medicine
Barbara L. Weber: University of Pennsylvania School of Medicine
Wafik S. El-Deiry: Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, University of Pennsylvania School of Medicine

Nature, 1997, vol. 389, issue 6647, 187-190

Abstract: Abstract Much of the predisposition to hereditary breast and ovarian cancer has been attributed to inherited defects in the BRCA1 tumour-suppressor gene1,2,3. The nuclear protein BRCA1 has the properties of a transcription factor4,5,6,7, and can interact with the recombination and repair protein RAD51 (ref. 8). Young women with germline alterations in BRCA1 develop breast cancer at rates 100-fold higher than the general population3, and BRCA1-null mice die before day 8 of development9,10. However, the mechanisms of BRCA1-mediated growth regulation and tumour suppression remain unknown. Here we show that BRCA1 transactivates expression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in a p53-independent manner, and that BRCA1 inhibits cell-cycle progression into the S-phase following its transfection into human cancer cells. BRCA1 does not inhibit S-phase progression in p21−/− cells, unlike p21+/+ cells, and tumour-associated, transactivation-deficient mutants of BRCA1 are defective in both transactivation of p21 and cell-cycle inhibition. These data suggest that one mechanism by which BRCA1 contributes to cell-cycle arrest and growth suppression is through the induction of p21.

Date: 1997
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/38291 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:389:y:1997:i:6647:d:10.1038_38291

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/38291

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().